BIOMARIN PHARMACEUTICAL INC (BMRN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 350M 700M 1.1B Q3 '16: 279.9M Q4 '16: 300.1M Q1 '17: 303.7M Q2 '17: 317.4M Q3 '17: 334.1M Q4 '17: 358.3M Q1 '18: 373.4M Q2 '18: 372.8M Q3 '18: 391.7M Q4 '18: 353.2M Q1 '19: 400.7M Q2 '19: 387.8M Q3 '19: 461.1M Q4 '19: 454.4M Q1 '20: 502.1M Q2 '20: 429.5M Q3 '20: 476.8M Q4 '20: 452.1M Q1 '21: 486M Q2 '21: 501.7M Q3 '21: 408.7M Q4 '21: 449.8M Q1 '22: 519.4M Q2 '22: 533.8M Q3 '22: 505.3M Q4 '22: 537.5M Q1 '23: 596.4M Q2 '23: 595.3M Q3 '23: 581.3M Q4 '23: 646.2M Q1 '24: 648.8M Q2 '24: 712M Q3 '24: 745.7M Q4 '24: 747.3M Q1 '25: 745.1M Q2 '25: 825.4M Q3 '25: 776.1M Q4 '25: 874.6M Q1 '26: 766.2M Q2 '26: 989.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 300M 600M 900M Q3 '16: 229.2M Q4 '16: 235.9M Q1 '17: 253.7M Q2 '17: 261.1M Q3 '17: 274.7M Q4 '17: 282.3M Q1 '18: 291.1M Q2 '18: 293.8M Q3 '18: 312.8M Q4 '18: 278.2M Q1 '19: 311.6M Q2 '19: 310.3M Q3 '19: 364.1M Q4 '19: 358.5M Q1 '20: 390.7M Q2 '20: 331.5M Q3 '20: 288M Q4 '20: 326M Q1 '21: 365.9M Q2 '21: 374.6M Q3 '21: 305.2M Q4 '21: 330.1M Q1 '22: 402.4M Q2 '22: 410.7M Q3 '22: 389.1M Q4 '22: 390.9M Q1 '23: 460.9M Q2 '23: 464.7M Q3 '23: 453.3M Q4 '23: 508.3M Q1 '24: 523.7M Q2 '24: 581.6M Q3 '24: 557.3M Q4 '24: 611.2M Q1 '25: 593.6M Q2 '25: 675.3M Q3 '25: 636M Q4 '25: 598.9M Q1 '26: 571.2M Q2 '26: 786.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-100M 0 100M 200M 300M Q3 '16: -60.1M Q4 '16: -89.6M Q1 '17: -20.2M Q2 '17: -38.8M Q3 '17: -13.7M Q4 '17: 58M Q1 '18: -44.4M Q2 '18: -25.3M Q3 '18: -15.7M Q4 '18: -38.1M Q1 '19: -54M Q2 '19: -41.4M Q3 '19: 4M Q4 '19: -9.2M Q1 '20: 105M Q2 '20: -40.9M Q3 '20: -55.9M Q4 '20: -51.5M Q1 '21: 25.1M Q2 '21: 11.7M Q3 '21: -53.2M Q4 '21: -65.9M Q1 '22: 137.3M Q2 '22: 39.2M Q3 '22: -2.4M Q4 '22: -13.1M Q1 '23: 62.4M Q2 '23: 65.6M Q3 '23: 30.5M Q4 '23: 27.3M Q1 '24: 88.5M Q2 '24: 120.5M Q3 '24: 113.9M Q4 '24: 161.4M Q1 '25: 223.9M Q2 '25: 276.9M Q3 '25: -46.7M Q4 '25: -44.6M Q1 '26: 129.6M Q2 '26: 110.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-300M 0 300M 600M 900M Q3 '16: -37.4M Q4 '16: -90.7M Q1 '17: -16.3M Q2 '17: -36.8M Q3 '17: -12.5M Q4 '17: -51.4M Q1 '18: -44.1M Q2 '18: -16.8M Q3 '18: -12.6M Q4 '18: -3.6M Q1 '19: -56.5M Q2 '19: -37.4M Q3 '19: 55M Q4 '19: 15M Q1 '20: 81.4M Q2 '20: -29.2M Q3 '20: 784.8M Q4 '20: 17M Q1 '21: 17.4M Q2 '21: 12.9M Q3 '21: -36.5M Q4 '21: -57.9M Q1 '22: 120.8M Q2 '22: 27.7M Q3 '22: -6.7M Q4 '22: -249K Q1 '23: 50.9M Q2 '23: 56M Q3 '23: 40.4M Q4 '23: 20.4M Q1 '24: 88.7M Q2 '24: 107.2M Q3 '24: 106.1M Q4 '24: 124.9M Q1 '25: 185.7M Q2 '25: 240.5M Q3 '25: -30.7M Q4 '25: -46.6M Q1 '26: 105.5M Q2 '26: 44.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 100M 200M 300M Q3 '16: 50.7M Q4 '16: 64.1M Q1 '17: 50M Q2 '17: 56.3M Q3 '17: 59.5M Q4 '17: 76M Q1 '18: 82.3M Q2 '18: 79M Q3 '18: 78.9M Q4 '18: 75M Q1 '19: 89.2M Q2 '19: 77.4M Q3 '19: 96.9M Q4 '19: 95.9M Q1 '20: 111.4M Q2 '20: 98M Q3 '20: 188.8M Q4 '20: 126.1M Q1 '21: 120.2M Q2 '21: 127.1M Q3 '21: 103.5M Q4 '21: 119.8M Q1 '22: 117M Q2 '22: 123.1M Q3 '22: 116.3M Q4 '22: 146.6M Q1 '23: 135.5M Q2 '23: 130.6M Q3 '23: 128M Q4 '23: 137.9M Q1 '24: 125.2M Q2 '24: 130.5M Q3 '24: 188.5M Q4 '24: 136.1M Q1 '25: 151.6M Q2 '25: 150.1M Q3 '25: 140.1M Q4 '25: 275.7M Q1 '26: 195M Q2 '26: 202.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-150M 0 150M 300M 450M Q3 '16: -10.4M Q4 '16: -210K Q1 '17: -80.4M Q2 '17: 18.8M Q3 '17: 38.3M Q4 '17: 14.6M Q1 '18: -42.5M Q2 '18: -33.9M Q3 '18: 47.2M Q4 '18: 49.4M Q1 '19: -54.9M Q2 '19: -24.3M Q3 '19: 70.1M Q4 '19: 57.3M Q1 '20: -15.2M Q2 '20: 27.7M Q3 '20: 86.2M Q4 '20: -13.4M Q1 '21: 113.5M Q2 '21: 82.8M Q3 '21: 97.1M Q4 '21: 11.2M Q1 '22: -45.4M Q2 '22: 56.2M Q3 '22: 158.3M Q4 '22: 6.8M Q1 '23: -73.9M Q2 '23: 70.1M Q3 '23: 135.6M Q4 '23: 27.5M Q1 '24: 47M Q2 '24: 118.8M Q3 '24: 221.5M Q4 '24: 185.6M Q1 '25: 174.4M Q2 '25: 185.3M Q3 '25: 368.7M Q4 '25: 99.6M Q1 '26: 220.7M Q2 '26: 168.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-150M 0 150M 300M 450M Q3 '16: -36.5M Q4 '16: -51.8M Q1 '17: -149.5M Q2 '17: -29M Q3 '17: -4.2M Q4 '17: -25.3M Q1 '18: -72.7M Q2 '18: -56.4M Q3 '18: -2.7M Q4 '18: 7.3M Q1 '19: -83.6M Q2 '19: -57M Q3 '19: 37.3M Q4 '19: 6.6M Q1 '20: -55.7M Q2 '20: 1.6M Q3 '20: 69.6M Q4 '20: -44.4M Q1 '21: 88M Q2 '21: 60.2M Q3 '21: 78.3M Q4 '21: -17.6M Q1 '22: -74.2M Q2 '22: 29.1M Q3 '22: 129M Q4 '22: -28.9M Q1 '23: -98.4M Q2 '23: 48.5M Q3 '23: 113.9M Q4 '23: -1.4M Q1 '24: 20.9M Q2 '24: 97.4M Q3 '24: 203M Q4 '24: 166.1M Q1 '25: 157.6M Q2 '25: 168.2M Q3 '25: 340.2M Q4 '25: 58.9M Q1 '26: 199.7M Q2 '26: 139.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q1 '12: 115.1M Q2 '12: 117.9M Q1 '13: 128M Q2 '13: 139.6M Q3 '13: 140.8M Q1 '14: 144.2M Q2 '14: 146.4M Q3 '14: 159.3M Q1 '15: 157.6M Q2 '15: 160.4M Q3 '15: 161.1M Q3 '16: 167.7M Q1 '17: 172.7M Q3 '17: 175.1M Q1 '18: 176.2M Q2 '18: 176.9M Q3 '18: 177.5M Q1 '19: 178.3M Q2 '19: 179M Q3 '19: 185.9M Q1 '20: 187.2M Q2 '20: 180.7M Q3 '20: 197.7M Q1 '21: 184.4M Q2 '21: 185.4M Q3 '21: 183.2M Q1 '22: 194.9M Q2 '22: 187.4M Q3 '22: 185.6M Q1 '23: 194.4M Q2 '23: 195M Q3 '23: 191.2M Q1 '24: 199.3M Q2 '24: 200.5M Q3 '24: 197.1M Q1 '25: 196.5M Q2 '25: 197.1M Q3 '25: 192M Q1 '26: 197.7M Q2 '26: 194.5M Q3 '13 Q2 '15 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '16: -2.84 Q4 '16: -3.82 Q1 '17: -3.40 Q2 '17: -1.03 Q3 '17: -0.88 Q4 '17: -0.66 Q1 '18: -0.83 Q2 '18: -0.71 Q3 '18: -0.71 Q4 '18: -0.44 Q1 '19: -0.50 Q2 '19: -0.62 Q3 '19: -0.25 Q4 '19: -0.13 Q1 '20: 0.63 Q2 '20: 0.68 Q3 '20: 4.39 Q4 '20: 4.40 Q1 '21: 4.05 Q2 '21: 4.28 Q3 '21: 0.07 Q4 '21: -0.36 Q1 '22: 0.18 Q2 '22: 0.26 Q3 '22: 0.42 Q4 '22: 0.73 Q1 '23: 0.37 Q2 '23: 0.51 Q3 '23: 0.76 Q4 '23: 0.87 Q1 '24: 1.06 Q2 '24: 1.32 Q3 '24: 1.66 Q4 '24: 2.21 Q1 '25: 2.70 Q2 '25: 3.38 Q3 '25: 2.67 Q4 '25: 1.80 Q1 '26: 1.39 Q2 '26: 0.39 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.